Stock CARM CARISMA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
1.64 USD 0.00% Intraday chart for Carisma Therapeutics, Inc. +0.61% -44.03%
04-11 BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target MT
04-02 HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating MT

Business Summary

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.

Number of employees: 107

Managers

Managers TitleAgeSince
Michael Klichinsky FOU
 Founder 34 31/12/15
Steven Kelly CEO
 Chief Executive Officer 59 31/01/18
Richard Morris DFI
 Director of Finance/CFO 51 31/05/21
Daniel Cushing CTO
 Chief Tech/Sci/R&D Officer - 31/12/16
Tom Wilton PRN
 Corporate Officer/Principal - 31/08/19
Terry Shields HRO
 Human Resources Officer - 13/06/23
Eric Siegel LAW
 General Counsel 60 13/06/23

Members of the board

Members of the board TitleAgeSince
Steven Kelly CEO
 Chief Executive Officer 59 31/01/18
Sanford Zweifach CHM
 Chairman 68 31/10/21
Björn Ingemar Odlander BRD
 Director/Board Member 66 31/01/22
Regina Hodits BRD
 Director/Board Member 54 31/05/18
Briggs Morrison BRD
 Director/Board Member 65 30/06/20
Michael Torok BRD
 Director/Board Member 45 06/03/23
John Hohneker BRD
 Director/Board Member 64 03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 41,542,534 27,945,479 ( 67.27 %) 0 67.27 %

Shareholders

NameEquities%Valuation
MODERNA, INC.
12.54 %
5,059,338 12.54 % 11 M $
HealthCap AB
8.421 %
3,398,248 8.421 % 8 M $
ABBVIE INC.
6.814 %
2,749,855 6.814 % 6 M $
IP Group Plc /Venture Capital/
6.723 %
2,713,232 6.723 % 6 M $
Regina Hodits
5.693 %
2,297,546 5.693 % 5 M $
Chidozie Ugwumba
5.491 %
2,215,877 5.491 % 5 M $
BlackRock Advisors LLC
4.433 %
1,789,037 4.433 % 4 M $
TPG Group Holdings (SBS) Advisors, Inc.
4.173 %
1,684,062 4.173 % 4 M $
Vanguard Fiduciary Trust Co.
3.887 %
1,568,761 3.887 % 4 M $
University of Pennsylvania (Investment)
3.103 %
1,252,107 3.103 % 3 M $

Company contact information

Carisma Therapeutics, Inc.

3675 Market Street Suite 200

19104, Philadelphia

+

http://carismatx.com
address Carisma Therapeutics, Inc.(CARM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Carisma Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.64 USD
Average target price
8.4 USD
Spread / Average Target
+412.20%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CARISMA THERAPEUTICS, INC. Stock Carisma Therapeutics, Inc.
-44.03% 68.13M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+0.55% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-8.98% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CARM Stock
  4. Company Carisma Therapeutics, Inc.